Literature DB >> 25143392

Dominant negative effect of polyglutamine expansion perturbs normal function of ataxin-3 in neuronal cells.

Andreia Neves-Carvalho1, Elsa Logarinho2, Ana Freitas1, Sara Duarte-Silva1, Maria do Carmo Costa3, Anabela Silva-Fernandes1, Margarida Martins1, Sofia Cravino Serra1, André T Lopes1, Henry L Paulson3, Peter Heutink4, João B Relvas2, Patrícia Maciel5.   

Abstract

The physiological function of Ataxin-3 (ATXN3), a deubiquitylase (DUB) involved in Machado-Joseph Disease (MJD), remains elusive. In this study, we demonstrate that ATXN3 is required for neuronal differentiation and for normal cell morphology, cytoskeletal organization, proliferation and survival of SH-SY5Y and PC12 cells. This cellular phenotype is associated with increased proteasomal degradation of α5 integrin subunit (ITGA5) and reduced activation of integrin signalling and is rescued by ITGA5 overexpression. Interestingly, silencing of ATXN3, overexpression of mutant versions of ATXN3 lacking catalytic activity or bearing an expanded polyglutamine (polyQ) tract led to partially overlapping phenotypes. In vivo analysis showed that both Atxn3 knockout and MJD transgenic mice had decreased levels of ITGA5 in the brain. Furthermore, abnormal morphology and reduced branching were observed both in cultured neurons expressing shRNA for ATXN3 and in those obtained from MJD mice. Our results show that ATXN3 rescues ITGA5 from proteasomal degradation in neurons and that polyQ expansion causes a partial loss of this cellular function, resulting in reduced integrin signalling and neuronal cytoskeleton modifications, which may be contributing to neurodegeneration.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25143392      PMCID: PMC4262494          DOI: 10.1093/hmg/ddu422

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  89 in total

1.  Evidence that integrins contribute to multiple stages in the consolidation of long term potentiation in rat hippocampus.

Authors:  D Chun; C M Gall; X Bi; G Lynch
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

Review 2.  Ubiquitin and the synapse.

Authors:  Ashok N Hegde; Aaron DiAntonio
Journal:  Nat Rev Neurosci       Date:  2002-11       Impact factor: 34.870

3.  Deubiquitinating function of ataxin-3: insights from the solution structure of the Josephin domain.

Authors:  Yuxin Mao; Francesca Senic-Matuglia; Pier Paolo Di Fiore; Simona Polo; Michael E Hodsdon; Pietro De Camilli
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-23       Impact factor: 11.205

4.  Ubiquitination of α-integrin cytoplasmic tails.

Authors:  Viola Hélène Lobert; Harald Stenmark
Journal:  Commun Integr Biol       Date:  2010-11-01

Review 5.  Integrins in cell migration.

Authors:  Anna Huttenlocher; Alan Rick Horwitz
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-09-01       Impact factor: 10.005

6.  Non-expanded polyglutamine proteins in intranuclear inclusions of hereditary ataxias--triple-labeling immunofluorescence study.

Authors:  T Uchihara; H Fujigasaki; S Koyano; A Nakamura; S Yagishita; K Iwabuchi
Journal:  Acta Neuropathol       Date:  2001-08       Impact factor: 17.088

7.  Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease.

Authors:  Anabela Silva-Fernandes; Sara Duarte-Silva; Andreia Neves-Carvalho; Marina Amorim; Carina Soares-Cunha; Pedro Oliveira; Kenneth Thirstrup; Andreia Teixeira-Castro; Patrícia Maciel
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 8.  Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system.

Authors:  James C Vickers; Anna E King; Adele Woodhouse; Matthew T Kirkcaldie; Jerome A Staal; Graeme H McCormack; Catherine A Blizzard; Ruth E J Musgrove; Stanislaw Mitew; Yao Liu; Jyoti A Chuckowree; Olivier Bibari; Tracey C Dickson
Journal:  Brain Res Bull       Date:  2009-08-13       Impact factor: 4.077

9.  Cyclin-dependent kinase-5 is involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal survival.

Authors:  Bing-Sheng Li; Wu Ma; Howard Jaffe; Yali Zheng; Satoru Takahashi; Lei Zhang; Ashok B Kulkarni; Harish C Pant
Journal:  J Biol Chem       Date:  2003-06-24       Impact factor: 5.157

10.  Regulation of retrotranslocation by p97-associated deubiquitinating enzyme ataxin-3.

Authors:  Qiuyan Wang; Lianyun Li; Yihong Ye
Journal:  J Cell Biol       Date:  2006-09-25       Impact factor: 10.539

View more
  9 in total

1.  Antisense oligonucleotide therapy rescues aggresome formation in a novel spinocerebellar ataxia type 3 human embryonic stem cell line.

Authors:  Lauren R Moore; Laura Keller; David D Bushart; Rodrigo G Delatorre; Duojia Li; Hayley S McLoughlin; Maria do Carmo Costa; Vikram G Shakkottai; Gary D Smith; Henry L Paulson
Journal:  Stem Cell Res       Date:  2019-07-16       Impact factor: 2.020

2.  Deficiency in classical nonhomologous end-joining-mediated repair of transcribed genes is linked to SCA3 pathogenesis.

Authors:  Anirban Chakraborty; Nisha Tapryal; Tatiana Venkova; Joy Mitra; Velmarini Vasquez; Altaf H Sarker; Sara Duarte-Silva; Weihan Huai; Tetsuo Ashizawa; Gourisankar Ghosh; Patricia Maciel; Partha S Sarkar; Muralidhar L Hegde; Xu Chen; Tapas K Hazra
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-23       Impact factor: 11.205

Review 3.  Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.

Authors:  Kritika Raj; Ravi Shankar Akundi
Journal:  Mol Neurobiol       Date:  2021-02-24       Impact factor: 5.590

4.  Tau and neurofilament light-chain as fluid biomarkers in spinocerebellar ataxia type 3.

Authors:  Hector Garcia-Moreno; Mercedes Prudencio; Gilbert Thomas-Black; Nita Solanky; Karen R Jansen-West; Rana Hanna Al-Shaikh; Amanda Heslegrave; Henrik Zetterberg; Magda M Santana; Luis Pereira de Almeida; Ana Vasconcelos-Ferreira; Cristina Januário; Jon Infante; Jennifer Faber; Thomas Klockgether; Kathrin Reetz; Mafalda Raposo; Ana F Ferreira; Manuela Lima; Ludger Schöls; Matthis Synofzik; Jeannette Hübener-Schmid; Andreas Puschmann; Sorina Gorcenco; Zbigniew K Wszolek; Leonard Petrucelli; Paola Giunti
Journal:  Eur J Neurol       Date:  2022-05-26       Impact factor: 6.288

5.  Broad Influence of Mutant Ataxin-3 on the Proteome of the Adult Brain, Young Neurons, and Axons Reveals Central Molecular Processes and Biomarkers in SCA3/MJD Using Knock-In Mouse Model.

Authors:  Kalina Wiatr; Łukasz Marczak; Jean-Baptiste Pérot; Emmanuel Brouillet; Julien Flament; Maciej Figiel
Journal:  Front Mol Neurosci       Date:  2021-06-17       Impact factor: 5.639

Review 6.  Ubiquitin signaling in neurodegenerative diseases: an autophagy and proteasome perspective.

Authors:  François Le Guerroué; Richard J Youle
Journal:  Cell Death Differ       Date:  2020-11-18       Impact factor: 12.067

7.  Ataxin-3 phosphorylation decreases neuronal defects in spinocerebellar ataxia type 3 models.

Authors:  Carlos A Matos; Clévio Nóbrega; Susana R Louros; Bruno Almeida; Elisabete Ferreiro; Jorge Valero; Luís Pereira de Almeida; Sandra Macedo-Ribeiro; Ana Luísa Carvalho
Journal:  J Cell Biol       Date:  2016-02-15       Impact factor: 10.539

8.  The Truncated C-terminal Fragment of Mutant ATXN3 Disrupts Mitochondria Dynamics in Spinocerebellar Ataxia Type 3 Models.

Authors:  Jung-Yu Hsu; Yu-Ling Jhang; Pei-Hsun Cheng; Yu-Fan Chang; Su-Han Mao; Han-In Yang; Chia-Wei Lin; Chuan-Mu Chen; Shang-Hsun Yang
Journal:  Front Mol Neurosci       Date:  2017-06-20       Impact factor: 5.639

9.  The Deubiquitinating Enzyme Ataxin-3 Regulates Ciliogenesis and Phagocytosis in the Retina.

Authors:  Vasileios Toulis; Sílvia García-Monclús; Carlos de la Peña-Ramírez; Rodrigo Arenas-Galnares; Josep F Abril; Sokol V Todi; Naheed Khan; Alejandro Garanto; Maria do Carmo Costa; Gemma Marfany
Journal:  Cell Rep       Date:  2020-11-10       Impact factor: 9.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.